Cabaletta Bio, Inc. (CABA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.35 |
| Open | 1.35 |
| Day High | 1.46 |
| Day Low | 1.32 |
| 52-Week High | 4.23 |
| 52-Week Low | 1.32 |
| Volume | 6.63M |
| Average Volume | 5M |
| Market Cap | 246.69M |
| PE | -0.93 |
| EPS | -1.57 |
| Moving Average 50 Days | 2.42 |
| Moving Average 200 Days | 2.87 |
| Change | 0.11 |
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio Announces 2026 Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automate